This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Arbutus (ABUS) Plunges on Disappointing HBV Pipeline Updates
by Zacks Equity Research
Arbutus Biopharma (ABUS) provides updates on its HBV development programs. However, uncertainty and early to mid-stage of development remains a concern.
Biotech Stock Roundup: GILD, BIIB Present Data, VTGN Gains on Fast Track Status
by Zacks Equity Research
Data presentations by leading sector players take center stage this week.
Gilead Sciences (GILD) Stock Moves -0.24%: What You Should Know
by Zacks Equity Research
In the latest trading session, Gilead Sciences (GILD) closed at $76.24, marking a -0.24% move from the previous day.
Merck Reports Positive Efficacy Data from Phase III HIV Study
by Zacks Equity Research
Merck (MRK) reports positive data from the phase III DRIVE-AHEAD study, evaluating Delstrigo in treatment-naive adults with HIV-1 infection.
Gilead Announces Positive Data From Ongoing Biktarvy Study
by Zacks Equity Research
Gilead (GILD) reports positive data from an ongoing late stage study on HIV regimen, Biktarvy at 96 weeks.
J&J's Phase III Data Shows Switch to its HIV Drug Beneficial
by Zacks Equity Research
Data from the 96-week long phase III EMERALD study shows that switching to J&J's (JNJ) Symtuza maintains high virologic suppression.
Gilead, HiFiBiO Collaborate to Develop T-Cell Receptors
by Zacks Equity Research
To boost its pipeline, Gilead (GILD) collaborates with HiFiBiO Therapeutics for the development of T-cell receptors.
Biotech Stock Roundup: ALXN on Acquisition Spree, FDA Nod for REGN, AMGN Drugs
by Zacks Equity Research
The biotech sector grabs headlines this week with FDA approvals plus licensing and acquisition pacts.
5 Top Healthcare Mutual Funds to Buy in October
by Zacks Equity Research
Successful drug trials at several biopharmas and FDA approvals make healthcare funds a strong investment option
5 Best Biotech Stocks to Buy In October
by Zacks Equity Research
Successful drug trials at several biopharmas and FDA approvals make biotech companies a strong investment choice in October
3 Biotech Stocks With Rising Estimates in the Past Month
by Zacks Equity Research
The biotech industry is performing reasonably well. Hence, it is a good idea to select stocks from the sector witnessing positive estimate revisions.
Guide to CRISPR Stocks & Latest Apple, Fed, GDP News | Free Lunch
by Ryan McQueeney
Ryan McQueeney highlights the Fed's latest rate hike sentiment and new revisions to GDP growth estimates. He also recaps Bed Bath & Beyond's earnings results and touches on analyst research related to Apple. Later, he is joined by Zacks' biotech guru, Kevin Cook, to chat about CRISPR stocks and how to invest in the developing science.
Alexion (ALXN) to Acquire Biotech Syntimmune for $1.2 Billion
by Zacks Equity Research
Alexion (ALXN) will acquire clinical-stage biotech company, Syntimmune for $1.2 billion to augment its rare disease pipeline.
Gilead Sciences (GILD) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Gilead Sciences (GILD) closed at $75.65, marking a +0.81% move from the previous day.
Biotech Stock Roundup: ALXN Soliris Successful, Respite For Sarepta, AMRN Soars
by Zacks Equity Research
Data read-outs by quite a few companies grabbed headlines in the biotech sector this week.
Gilead (GILD) to Launch Generics for Leading HCV Treatments
by Zacks Equity Research
Given the persistent decline in HCV sales, Gilead (GILD) plans to launch authorized generic versions of its leading hepatitis C virus (HCV) treatments, Epclusa and Harvoni.
Exelixis, Ipsen Receive Positive CHMP Opinion for Cabometyx
by Zacks Equity Research
Exelixis, Inc. (EXEL) and partner Ipsen get a positive opinion from the CHMP for Cabometyx tablets as a monotherapy for the second-line treatment of hepatocellular carcinoma in adults.
CHMP Reconfirms Negative Opinion for Sarepta's Exondys
by Zacks Equity Research
The CHMP re-confirmed the negative opinion for Sarepta's (SRPT) Exondys, which is developed to treat individuals who have a specific type of Duchenne muscular dystrophy.
Rubius (RUBY) in Focus: Stock Moves 8.7% Higher
by Zacks Equity Research
Rubius (RUBY) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.
FDA Confirms Positive Safety Profile of Acadia's Nuplazid
by Zacks Equity Research
Acadia's shares soar more than 20% as the FDA issues a statement reaffirming the positive benefit-risk profile of Nuplazid for patients with Parkinson's disease psychosis.
Exelixis' Partner Ipsen Gets Approval for Cabometyx in Canada
by Zacks Equity Research
Exelixis (EXEL) and partner Ipsen Biopharmaceuticals Canada gain approval for Cabometyx from Health Canada for the treatment of advanced renal cell carcinoma in adult patients.
Ultragenyx's Shares Surge More Than 80% in the Year So Far
by Zacks Equity Research
Ultragenyx's (RARE) share price has increased by about 85.2% year to date based on some positive developments for the product candidates of the company.
Molecular Templates Surges 50%, Inks Cancer Deal With Takeda
by Zacks Equity Research
Molecular Templates (MTEM) signs a collaborative contract with Japan's Takeda for jointly developing CD38-targeted engineered toxin antibodies to treat multiple myeloma. The stock soars past 50%.
The Zacks Analyst Blog Highlights: Regeneron Pharmaceuticals, Celgene, Sanofi and Gilead Sciences
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Regeneron Pharmaceuticals, Celgene, Sanofi and Gilead Sciences
Gilead Sciences (GILD) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Gilead Sciences (GILD) closed at $73.88, marking a +0.31% move from the previous day.